Detecting circulating tumor cells (CTCs) remains a significant analytical challenge due to their extreme rarity. Only about 1–10 CTCs are typically present per mL of whole blood, and current technologies often must identify a single CTC among nearly 10 million nucleated blood cells. This rarity drives the need for highly sensitive platforms capable of resolving these exceptionally scarce events.
The Axon Dx imaging systems were originally developed to address the technical challenges of circulating tumor cell (CTC) detection and have evolved into adaptable rare-cell research platforms.
Key capabilities include:
Axon Dx’s nCyte™ technology scans un-enriched blood samples in minutes, finds all classes of rare cells such as CTCs shed by solid tumors, and offers morphological and proteomic and genomic characterization of positive cells.
Axon Dx engages in research collaborations and strategic technology partnerships within the rare-cell detection ecosystem.